



CCPE Review Rubric



Overview

The goal of the review is for AAAAI to provide educational content that is free of commercial bias and follows ACCME guidelines. Additionally, learners should be presented with accurate, balanced and scientifically sound recommendations.

CCPE's role is not meant to be punitive but rather to provide guidelines to allow speakers, moderators, and planners to participate in educational activities while maintaining a bias-free and objective approach that serves the needs of healthcare professionals and patients, not the interests of industry.

Individuals who may be in a position to control accredited continuing education are expected to disclose all their financial relationships with ineligible companies within the past 24 months to the provider.



An ineligible company are those whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found <https://www.accme.org/faq/what-accmes-definition-ineligible-company>

Guidelines

All financial relationships should be disclosed	Regardless of monetary value or amount
Employees / owners of ineligible companies	Not allowed in any capacity
Relevant relationships	Only those related to the content of the educational activity will be mitigated
Equity considerations	Owning stock in a <i>privately</i> held ineligible company considered an owner. Must be excluded from controlling content. Owning stock in a <i>publicly</i> traded ineligible company not considered an owner.
Speakers Bureau	Allowed, but closely reviewed for potential bias
Exceptions	Research grants from federal funding sources (should be disclosed by faculty- although not considered a conflict), primary university appointments, ownership or employment at private practice offices.

Mitigation Strategies

Generally, for owners/ employees of ineligible companies or conflicts that are not able to mitigated- they must be removed from influence over the educational content and new faculty/ authors must be selected, who do not have a conflict of interest.

Meeting Planners

Individual is asked to alter the relationship with the ineligible company so that the individual no longer has a relevant relationship, OR IF NOT POSSIBLE

- Individual must recuse themselves from involvement in the planning of activities specifically related to the conflict identified.

Speakers/ Moderators

Individual is asked to alter the relationship with the ineligible company so that the individual no longer has a relevant relationship, OR IF NOT POSSIBLE

Individual is asked to alter the activity's content with regard to products or services of the ineligible company through one of the following:

- For disease states that include diagnostics/treatment with multiple options available
 - Focus content of the activity to include recommendations from multiple and balanced sources, citing evidence based medicine
- For disease states that include diagnostics/treatment with limited options available
 - Focus the content of the activity to a report of the data and results of research, without recommendations
- For disease states that don't include discussion of diagnostic/ treatment options
 - Limit the content of the activity to avoid references to the products or services of the ineligible company
- For any relationship with a strong potential for conflict or without adequate detail to mitigate
 - Provide slides/ content for a peer review

Examples

Dr. X is a consultant with an ongoing financial relationship with Regeneron specific to Dupixent for the treatment of atopic dermatitis. The talk will include a discussion on the management of atopic dermatitis.

As multiple treatment approaches are available, the speaker is requested to focus the content of the activity to include recommendations from multiple and balanced sources, citing evidence-based medicine

Dr. X is a consultant with an ongoing financial relationship with Regeneron specific to Dupixent for the treatment of eosinophilic esophagitis. The talk will include a discussion on the management of eosinophilic esophagitis.

As there are very limited treatment options, the speaker is requested to focus the content of the activity to a report of the data and results of the research, without recommendations.

Dr. X is a consultant with an ongoing financial relationship with Regeneron specific to Dupixent for the treatment of atopic asthma. The talk will include a discussion on T2 inflammation in atopic asthma without discussion of treatment.

With no discussions of treatment options, the speaker is requested to limit the content of the activity to avoid references to the products or services of the commercial interest(s)

Dr. X is a consultant with an equity interest in Regeneron (*publicly traded*). The talk will include a discussion on T2 inflammation in atopic asthma without discussion of treatment.

With an equity interest in the ineligible company, the speaker is requested to provide slides for peer review of content.

Dr. X is a on a speakers bureau for Regeneron. The talk will include a discussion on T2 inflammation in atopic asthma without discussion of treatment.

As a speaker promoting a product from an ineligible company, the speaker is requested to provide slides for peer review of content.



Resources

ACCME Guidelines

<https://www.accme.org/accreditation-rules/standards-for-integrity-independence-accredited-ce>

Online Disclosure Review System

<https://aaaai.execinc.com/disclosure-review/>

AAAAI Disclosure Policy

<https://aaaai.execinc.com/disclosure/>

For any questions- please contact CCPE staff liaisons:

Taunya Due tdue@aaaai.org 414-272-6071

Rachelle Hoehnen rhoehnen@aaaai.org 414-272-6071

July 2024